Principles of tumorigenesis and emerging molecular drivers of SHH‐activated medulloblastomas
Abstract SHH‐activated medulloblastomas (SHH‐MB) account for 25–30% of all medulloblastomas (MB) and occur with a bimodal age distribution, encompassing many infant and adult, but fewer childhood cases. Different age groups are characterized by distinct survival outcomes and age‐specific alterations...
Main Authors: | Otília Menyhárt, Balázs Győrffy |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Annals of Clinical and Translational Neurology |
Online Access: | https://doi.org/10.1002/acn3.762 |
Similar Items
-
Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas
by: Otília Menyhárt, et al.
Published: (2019-03-01) -
The transcriptional landscape of Shh medulloblastoma
by: Patryk Skowron, et al.
Published: (2021-03-01) -
Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
by: Zhen-Yu Zhang, et al.
Published: (2014-01-01) -
Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis
by: Otília Menyhárt, et al.
Published: (2021-01-01) -
Drug Delivery Systems for Hedgehog Inhibitors in the Treatment of SHH-Medulloblastoma
by: Miriam Caimano, et al.
Published: (2021-06-01)